Comparing Todos Medical (OTCMKTS:TOMDF) & Perspective Therapeutics (NYSE:CATX)

Todos Medical (OTCMKTS:TOMDF) and Perspective Therapeutics (NYSE:CATX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings.

Profitability

This table compares Todos Medical and Perspective Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Todos Medical	N/A	N/A	N/A
Perspective Therapeutics	-4,096.66%	-27.40%	-23.16%

Volatility & Risk

Todos Medical has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500. Comparatively, Perspective Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500.

Earnings and Valuation

This table compares Todos Medical and Perspective Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Todos Medical	$12.23 million	0.02	-$43.31 million	N/A	N/A
Perspective Therapeutics	$1.43 million	372.44	-$46.51 million	N/A	N/A

Todos Medical has higher revenue and earnings than Perspective Therapeutics.

Analyst Ratings

This is a breakdown of current recommendations for Todos Medical and Perspective Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Todos Medical	0	0	0	0	0.00
Perspective Therapeutics	0	0	9	0	3.00

Perspective Therapeutics has a consensus target price of $21.57, suggesting a potential upside of 173.75%. Given Perspective Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Perspective Therapeutics is more favorable than Todos Medical.

Institutional and Insider Ownership

54.7% of Perspective Therapeutics shares are owned by institutional investors. 3.5% of Perspective Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Perspective Therapeutics beats Todos Medical on 7 of the 12 factors compared between the two stocks.

About Todos Medical

Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.

About Perspective Therapeutics

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.